Vaccines in pregnancy

Infectious Disease Clinics of North America

Volumn 15, Issue 1, 2001, Pages 253-271

  Munoz, Flor M ^a   Englund, Janet A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID; VACCINE; YELLOW FEVER VACCINE;

BACTERIAL INFECTION; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HEALTH EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INFECTION PREVENTION; NEWBORN INFECTION; PREGNANCY COMPLICATION; REVIEW; VACCINATION; VIRUS INFECTION;

EID: 0035057161     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70278-6     Document Type: Article

References (85)

1. Hamnophilus influenzae type b in the western region of the Gambia: Background surveillance for a vaccine efficacy trial
2. The potential for maternal immunization to protect against neonatal infections
3. Fetal-neonatal passive immunization against Haemophilus influenzae type b
4. Immunization of pregnant women with polysaccharide vaccine of group B streptococcus
5. Safety and immunogenicity of capsular polysaccharide - Tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib
6. The efficacy of live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine in children
7. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: Clinical and immune responses to subsequent natural infection in children
8. Haemophilus influenzae invasive disease in the United States, 1994-1995: Near disappearance of a vaccine-preventable childhood disease
9. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na
10. Respiratory syncytial virus in early infancy: Circulating antibody and the severity of infection
11. The guinea pig as a model for the study of maternal immunization against respiratory syncytial virus infection in infancy
12. Fetal damage after accidental polio vaccination of an immune mother
13. Prevention and control of influenza
14. Pertussis - United States, January 1992-June 1995
15. Serious respiratory tract disease caused by respiratory syncytial virus: Prospects for improved therapy and effective immunization
16. Poliomyelitis prevention in the United States: Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)
17. Poliovirus infections
18. Response of pregnant women and their infants to poliomyelitis vaccine. Distribution of poliovirus antibody in pregnant women before and after vaccination. Transfer, persistence and induction of antibodies in infants
19. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines
20. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants
21. Maternal immunization against viral disease
22. Haemophilus influenzae type b-specific antibody in infants after maternal immunization
23. Pneumococcal carriage in infants following maternal immunization with pneumococcal vaccine or Haemophilus influenzae type b conjugate vaccine during pregnancy
24. Serum immunoglobulin levels in premature and full term infants
25. Antibody to varicella-zoster virus in parturient women and their offspring during the first year of life
26. Maternal immunization with the capsular polysaccharide vaccine for Haemophilus influenzae type b
27. Influenza virus
28. Risk of respiratory syncytial virus infection for infants from low-income families in relation to age, sex, ethnic group, and maternal antibody level
29. Global programme for vaccines and immunization
30. Immunization of high risk infants younger than 18 months of age with split-product influenza vaccine
31. Occurrence of groups A and B respiratory syncytial virus over 15 years: Associated epidemiologic and clinical characteristics in hospitalized and ambulatory children
32. Oral polio vaccination during pregnancy: Lack of impact on fetal development and perinatal outcome
33. Oral polio vaccination during pregnancy: No increase in the occurrence of congenital malformations
34. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy
35. Immunizing agents
36. Viremia in infants vaccinated with oral poliovirus vaccine (Sabin)
37. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
38. A live parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
39. A live attenuated bovine parainfluenza type 3 virus vaccine is safe, infectious, immunogenic and phenotypically stable in healthy infants and children
40. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children
41. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine
42. Pertussis in adolescents and adults: Time to reimmunize?
43. Immune response of mothers and babies to injections of pertussis vaccine during pregnancy
44. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
45. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection
46. Elevation of cord over maternal IgG immunoglobulin - Evidence for an active placental IgG transport
47. Maternal peripartum complications associated with vaginal group B streptococci colonization
48. Meningococcal vaccine in pregnancy: An assessment of infant risk
49. Effect of maternal immunization with oral poliovirus vaccine on neonatal immunity
50. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes
51. Transport of proteins across the human placenta
52. Antibody response to serogroup A and C meningococcal vaccines in infants born to mothers vaccinated during pregnancy
53. Maternal immunization for the prevention of bacterial infection in young infants
54. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia
55. Effect of third trimester maternal immunization with H. influenzae type b conjugate vaccine in the infant's immune response to primary immunization
56. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children
57. Influenza-associated morbidity and mortality in young and middle-aged women
58. Menigococcal antibody titers in infants of women immunized with meningococcal polysaccharide vaccine during pregnancy
59. Immunization with a pneumococcal polysaccharide vaccine during pregnancy
60. Maternal antibody and respiratory syncytial virus infection in infancy
61. Congenital anomalies after oral poliovirus vaccination during pregnancy
62. Safety and immunogenicity of the PFP vaccine against RSV: The Western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection
63. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis
64. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
65. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections
66. Protection of infants from infection with influenza A virus by transplacentally acquired antibody
67. An international conference on the application of vaccines against viral, rickettsial and bacterial diseases of man
68. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine
69. Half life of maternal IgG1 allotype in infants
70. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis
71. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children
72. Poliomyelitis in pregnancy: Effect on fetus and newborn infant
73. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: Influence of adjuvants and maternal antibodies
74. Identification of mutations contributing to the temperature sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine
75. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine
76. Efficacy, safety, and immunogenicity of heptavalent pneumococcal vaccine in children
77. Prospects for control of herpes simplex virus disease through immunization
78. Immunoprophylaxis of respiratory syncytial virus infection in the infant ferret
79. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
80. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus in high risk infants
81. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old
82. Congenital yellow fever virus infection after immunization in pregnancy
83. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections
84. Protection from respiratory syncytial viral infection in cotton rats by viral glycoprotein subunit immunization
85. Antibodies to respiratory syncytial virus polypeptides and their significance in human infection